Skip to main content
Delfa

← All trials/NCT07650149

OPTIMIZE-GEN

Recruiting

Genetic, Microbiological and Behavioral Factors in Obesity

OPTIMIZE GEN - Outcomes of Persistence and Treatment With tIrzepatide deterMined by Genetic, mIcrobiological & bEhavioral Factors in obEsity

Asset

Tirzepatide

Subcutaneous · GLP-1 / GIP dual

Listed sites

2

Recruiting sites

2

Estimated enrollment

200

Study population

Obesity / overweight

Eligibility highlights

•BMI ≥27

Primary endpoint

•Weight change

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07650149
Org study ID1/2026 of 6.05.2026

Timeline

Milestones

Study start2026-05-23actual
Study first posted2026-06-16actual
Last update posted2026-06-16actual
Primary completion2027-05estimated (month precision)
Study completion2028-05estimated (month precision)

Assets

Investigational agents

Tirzepatide

Who this study enrolls

Obesity / overweight

Who can enroll

Minimum age18 Years
Maximum age60 Years
SexAll
Healthy volunteersNot accepted
Sampling methodNon probability sample

Study population text

Patients who are overweight or obese and were prescribed tirzepatide for their treatment

Inclusion criteria

•Age 18-60 years
•Consent to participate in the study and providing informed written consent
•Overweight or obese with a BMI >27

Exclusion criteria

•Contraindications to tirzepatide use:
•Type 1 or type 2 diabetes
•Pregnancy or breastfeeding
•Cancer
•Heart failure
•Expected lack of patient compliance
•Taking immunosuppressive medications, steroids, NSAIDs, antibiotics (within 2 weeks prior to sample collection),
•Autoimmune and inflammatory diseases, acute infectious diseases, AIDS, tuberculosis
•Mental illness
•Alcohol dependence syndrome
•Liver cirrhosis
•Post-myocardial infarction or stroke

Endpoints (3)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other (unclassified)
2
Weight & body composition
1

Weight & body composition

1 endpoint
Primary/protocol endpoint

weight change

Time frame:1 and 6 months

descriptive

Other (unclassified)

2 endpoints
Secondary/protocol endpoint/low confidence

treatment discontinuation

Time frame:up to 6 months

descriptive

Secondary/protocol endpoint/low confidence

adverse reactions

Time frame:up to 6 months

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 6, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.